KZIA earnings: next report 2026-09-04, real EPS beat/miss history, analyst consensus Buy, P/E -2.01. Updated 2026-07-23.
Kazia Therapeutics (KZIA) Research Hub
Kazia Therapeutics (KZIA) trades on NASDAQ, AU in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.19 USD (-5.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.01, market cap 0.02B. This hub links to the full technical, earnings and options research available for KZIA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, AU |
| Last close | 11.19 USD (-5.81%) |
| 52-week range | 10.835 USD – 15.5 USD |
| Trend regime | Range |
| 14-day RSI | 31 (Bearish) |
| Trailing P/E | -2.01 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-04 |
Available research for KZIA
Covered Call on KZIA: how it works, illustrative setup around the real 11.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KZIA: how it works, illustrative setup around the real 11.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KZIA: how it works, illustrative setup around the real 11.19 USD price, max profit/loss, breakeven and when to use it. Educational.
KZIA technical analysis: range, last 11.19 USD, RSI 31, 52w range 10.835 USD–15.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KZIA in?
Kazia Therapeutics (KZIA) is classified under Healthcare (Biotechnology), listed on NASDAQ, AU.
Is KZIA in an uptrend or downtrend?
As of 2026-09-11, KZIA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KZIA's trailing P/E ratio?
KZIA's trailing P/E is -2.01, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does KZIA next report earnings?
KZIA is next scheduled to report earnings on 2026-09-04, with a consensus EPS estimate of -0.69729 USD.